EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chairman, President and CEO Mark M. Sieczkarek is scheduled to present a corporate overview at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
Avenova
is formulated with Neutrox®, which is cleared by the U.S.
Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox
is NovaBay’s commercial name for its proprietary pure hypochlorous acid.
Data from a multicenter clinical study show that Avenova reduced
bacterial load, the underlying cause of blepharitis, on ocular skin
surface by more than 90%. Laboratory tests show that hypochlorous acid
has potent antimicrobial activity in solution yet is non-toxic to
mammalian cells and also neutralizes bacterial toxins. Avenova is
marketed to optometrists and ophthalmologists throughout the U.S. by
NovaBay’s direct salesforce. It is accessible from more than 90% of
retail pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmerisourceBergen.
Stay informed on NovaBay's progress:
Download
our Mobile InvestorApp from the Apple
Store or Google
Play
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit
NovaBay's
Website